Broad In­sti­tute's drug dis­cov­ery arm starts see­ing the fruit of its la­bor en­ter the clin­ic

The Broad In­sti­tute of MIT and Har­vard is known for push­ing the bound­aries of sci­ence, with its CRISPR-based dis­cov­er­ies and cut­ting edge re­searchers.

But one of the less­er-known sides of the in­sti­tute in­cludes a drug dis­cov­ery en­gine, which has now forged col­lab­o­ra­tions with four ma­jor in­dus­try part­ners ⁠— Bay­er, Cal­i­co, No­vo Hold­ings and Deer­field. It’s now see­ing its first on­col­o­gy can­di­dates en­ter the clin­ic, and look­ing for more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER